Elisabeth Oelmann
Chief Tech/Sci/R&D Officer bei NUCANA PLC
Profil
Elisabeth Oelmann is currently the Senior VP-Medical & Clinical Development at NuCana Plc since 2020.
Prior to this, she worked as a Senior Medical Director at Kymab Ltd.
and as a Medical Director-Oncology Europe Region at PRA International LLC.
She also worked as a Professor at Freie Universität Berlin.
Dr. Oelmann holds a doctorate degree from the University of Münster.
Aktive Positionen von Elisabeth Oelmann
| Unternehmen | Position | Beginn |
|---|---|---|
| NUCANA PLC | Chief Tech/Sci/R&D Officer | 01.09.2020 |
Ehemalige bekannte Positionen von Elisabeth Oelmann
| Unternehmen | Position | Ende |
|---|---|---|
PRA International LLC
 PRA International LLC Pharmaceuticals: OtherHealth Technology Part of ICON plc, PRA International LLC is a clinical research organization. The private company is based in Raleigh, NC. | Corporate Officer/Principal | - |
| Freie Universität Berlin | Corporate Officer/Principal | - |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Elisabeth Oelmann
| University of Münster | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NUCANA PLC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
PRA International LLC
PRA International LLC Pharmaceuticals: OtherHealth Technology Part of ICON plc, PRA International LLC is a clinical research organization. The private company is based in Raleigh, NC. | Health Technology |
